Dr. J. Joseph Marr

• 
  www.qbius.com/Modules/Main/?TemplateID=5&PageID=105 - [Cached Version]
  Published on: 10/3/2007    Last Visited: 10/3/2007  

  FREMONT, Calif., Sept. 4 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that J. Joseph Marr, M.D. has been appointed as the Company's new Chief Medical Officer. In this capacity, Dr. Marr will play a key role in supporting Quark's current clinical programs and in outlining the goals and plans of the Company's pipeline. Prior to joining Quark, Dr. Marr served as President of BioMed, LLC, a medical and biotechnology consulting company, since 1999.He simultaneously served as General Partner of Pacific Rim Ventures, a venture capital firm, since 2000.Previously, Dr. Marr held positions at Immulogic Pharmaceutical Corporation from 1996 to 1999, serving most recently as President, CEO, and member of the Board of Directors.Dr. Marr previously served as Vice President, Research and Development of Ribozyme Pharmaceuticals, Inc. and as Senior Vice President, Discovery Research at Monsanto Searle Research and Development.Dr. Marr received a Doctorate of Medicine from The Johns Hopkins University School of Medicine and has held professorial positions at University of Colorado Health Sciences Center, St. Louis University School of Medicine, and Washington University School of Medicine.
  ...
  Marr brings to Quark nearly 20 years experience in clinical research positions at note worthy pharmaceutical companies, including Immulogic and Ribozyme.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=68389 - [Cached Version]
  Published on: 9/4/2007    Last Visited: 9/4/2007  

  FREMONT, Calif., Sept. 4 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that J. Joseph Marr, M.D. has been appointed as the Company's new Chief Medical Officer.
  
  In this capacity, Dr. Marr will play a key role in supporting Quark's current clinical programs and in outlining the goals and plans of the Company's pipeline.
  
  Prior to joining Quark, Dr. Marr served as President of BioMed, LLC, a medical and biotechnology consulting company, since 1999.He simultaneously served as General Partner of Pacific Rim Ventures, a venture capital firm, since 2000.Previously, Dr. Marr held positions at Immulogic Pharmaceutical Corporation from 1996 to 1999, serving most recently as President, CEO, and member of the Board of Directors.Dr. Marr previously served as Vice President, Research and Development of Ribozyme Pharmaceuticals, Inc. and as Senior Vice President, Discovery Research at Monsanto Searle Research and Development.Dr. Marr received a Doctorate of Medicine from The Johns Hopkins University School of Medicine and has held professorial positions at University of Colorado Health Sciences Center, St. Louis University School of Medicine, and Washington University School of Medicine.
  ...
  Marr brings to Quark nearly 20 years experience in clinical research positions at note worthy pharmaceutical companies, including Immulogic and Ribozyme.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 9/4/2007    Last Visited: 9/6/2007  

  J. Joseph Marr, M.D. has been appointed as the Company's new Chief Medical Officer. In this capacity, Dr. Marr will play a key role in supporting Quark's current clinical programs and in outlining the goals and plans of the Company's pipeline. Prior to joining Quark, Dr. Marr served as President of BioMed, LLC, a medical and biotechnology consulting company, since 1999.He simultaneously served as General Partner of Pacific Rim Ventures, a venture capital firm, since 2000.Previously, Dr. Marr held positions at Immulogic Pharmaceutical Corporation from 1996 to 1999, serving most recently as President, CEO, and member of the Board of Directors.Dr. Marr previously served as Vice President, Research and Development of Ribozyme Pharmaceuticals, Inc. and as Senior Vice President, Discovery Research at Monsanto Searle Research and Development.Dr. Marr received a Doctorate of Medicine from The Johns
  ...
  Marr brings

• 
  www.24x7mag.com/press_release.asp?id=10141283 - [Cached Version]
  Published on: 9/4/2007    Last Visited: 9/4/2007  

  /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that J. Joseph Marr
  
  , M.D. has been appointed as the Company's new Chief Medical Officer.
  
  In this capacity, Dr. Marr
  
  will play a key role in supporting Quark's current clinical programs and in outlining the goals and plans of the Company's pipeline.
  
  Prior to joining Quark, Dr. Marr
  
  served as President of BioMed, LLC, a medical and biotechnology consulting company, since 1999.He simultaneously served as General Partner of Pacific Rim Ventures, a venture capital firm, since 2000.Previously, Dr. Marr
  
  held positions at Immulogic Pharmaceutical Corporation from 1996 to 1999, serving most recently as President, CEO, and member of the Board of Directors.Dr. Marr
  
  previously served as Vice President, Research and Development of Ribozyme Pharmaceuticals, Inc. and as Senior Vice President, Discovery Research at Monsanto Searle Research and Development.Dr. Marr
  ...
  Marr

• 
  sanjose.bizjournals.com/sanjose/stories/2007/09/03/dail - [Cached Version]
  Published on: 9/4/2007    Last Visited: 9/5/2007  

  BioMed LLC, Quark Pharmaceuticals Inc., Dr. Shai Erlich, Dr. Joseph Marr,
  ...
  Quark Pharmaceuticals Inc. named Dr. Joseph Marr as its first chief medical officer on Tuesday.
  
  Marr worked previously at BioMed LLC, a consulting company, and he was a general partner at Pacific Rim Ventures.He also worked at Immulogic Pharmaceutical Corp.

• 
  sanfrancisco.bizjournals.com/sanfrancisco/stories/2007/ - [Cached Version]
  Published on: 9/4/2007    Last Visited: 9/5/2007  

  BioMed LLC, ImmuLogic Pharmaceutical Corp., Quark Pharmaceuticals Inc., Joseph Marr, Dr. Shai Erlich,
  ...
  Quark Pharmaceuticals Inc. named Joseph Marr, M.D., as its first chief medical officer.
  
  Marr worked previously at BioMed LLC, a consulting company, and he was a general partner at Pacific Rim Ventures.He also worked at Immulogic Pharmaceutical Corp.

• 
  www.marijuanalibrary.org/980416.html - [Cached Version]
  Published on: 4/16/1998    Last Visited: 12/5/2007  

  addiction," Dr. Joseph Marr, ImmuLogic's president, said in a statement.

• 
  Bacterial Barcodes - [Cached Version]
  Published on: 12/8/2002    Last Visited: 12/8/2002  

  J. Joseph Marr, M.D.
  
  General Partner, Pacific Rim Ventures Chief Executive Officer - Immulogic Pharmaceutical

• 
  NutriMedical Online Database of Nutritional Supplements - [Cached Version]
  Published on: 5/15/2006    Last Visited: 10/8/2006  

  ImmuLogic is pleased to have been able to enlist the scientific and clinical talent at Cantab in the further development of these vaccines which address such significant medical and social problems," said J. Joseph Marr, M.D., President and Chief Executive Officer of ImmuLogic.
  
  Dr. Marr added, "This year, ImmuLogic has been quite successful in concluding corporate arrangements with Sankyo, Heska Corporation, and now Cantab Pharmaceuticals.

• 
  PRV-Partners - [Cached Version]
  Published on: 1/11/2007    Last Visited: 5/6/2007  

  J. Joseph Marr, M.D.
  
  Proir to joining PRV, Dr. Marr was President and CEO, Immulogic Pharmaceutical Corporation, Waltham, MA (NASDAQ:IMUL).Previously, Dr. Marr was VP Research and Development and Chief Scientific Officer, Ribozyme Pharmaceuticals, Inc.(currently Sirna Therapeutics), Boulder, CO (NASDAQ:RZYM); and Senior VP, Discovery Research of Monsanto/Searle (currently Pfizer), St. Louis, MO.Dr. Marr is board-certified in Internal Medicine and Infectious Diseases.He has held faculty positions as Professor of Medicine and Biochemistry at U. of Colorado Health Sciences Center, St. Louis University School of Medicine, and Washington University School of Medicine.Dr. Marr received his M.D. degree at the Johns Hopkins University School of Medicine, and his M.S. (Research) degree in Microbial Biochemistry at St. Louis University Graduate School, Department of Microbiology and studied molecular biology at the Eleanor Roosevelt Cancer Institute in Denver, CO.His research has been published in Science, Journal of Biological Chemistry, New England J. of Medicine, J. of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

Page:  1 2